GOLGA6L6 Inhibitors
GOLGA6L6 inhibitors belong to a specific chemical class designed to modulate the activity of the Golgin subfamily A member 6-like 6 (GOLGA6L6) protein. GOLGA6L6 is a member of the golgin family, which plays a crucial role in maintaining the structure and function of the Golgi apparatus, a cellular organelle responsible for protein sorting and modification. The Golgi apparatus is pivotal in intracellular transport and secretion processes, making it a vital component in cellular homeostasis.
The inhibitors designed for GOLGA6L6 target specific binding sites or pathways associated with the protein, aiming to disrupt or attenuate its normal function. By impeding GOLGA6L6 activity, these inhibitors may influence the organization and dynamics of the Golgi apparatus, subsequently affecting cellular processes dependent on proper Golgi function. The development and study of GOLGA6L6 inhibitors contribute to our understanding of intracellular trafficking mechanisms and provide valuable tools for investigating the broader cellular implications of Golgi dysfunction. Researchers focus on elucidating the molecular interactions between GOLGA6L6 and its inhibitors, unraveling the intricate details of the protein's role in cellular processes. This chemical class represents a targeted approach to manipulate the intricate machinery of the Golgi apparatus at the molecular level, shedding light on the underlying biological processes and paving the way for the development of novel research tools.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Pioglitazone | 111025-46-8 | sc-202289 sc-202289A | 1 mg 5 mg | $55.00 $125.00 | 13 | |
Pioglitazone activates peroxisome proliferator-activated receptor gamma (PPARγ), which can influence the expression of various genes. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Flavopiridol inhibits cyclin-dependent kinases (CDKs) and could alter cell cycle progression, influencing gene expression. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is an EGFR inhibitor that may affect downstream signaling pathways, potentially resulting in altered gene expression. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 selectively inhibits MEK, which can lead to a decrease in ERK pathway signaling and potentially reduce gene expression. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that can block the Akt signaling pathway, potentially leading to decreased protein synthesis. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor that may result in altered transcription factor activity and gene expression. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 inhibits p38 MAP kinase, affecting cytokine production and potentially modulating gene expression. | ||||||
17-AAG | 75747-14-7 | sc-200641 sc-200641A | 1 mg 5 mg | $67.00 $156.00 | 16 | |
17-AAG inhibits Hsp90, which plays a crucial role in the proper folding of many proteins, including some that regulate gene expression. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
Selumetinib is a MEK inhibitor that can affect the MAPK/ERK signaling pathway, potentially impacting gene expression. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $90.00 $204.00 | 13 | |
Triptolide has been shown to inhibit the transcription of various genes, potentially through multiple mechanisms. | ||||||